title: Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
authors.forename: Caitlin
authors.initials: C
authors.lastname: Reed
authors.forename: Ashraf
authors.initials: A
authors.lastname: Ibrahim
authors.forename: John E
authors.initials: JE
authors.lastname: Edwards
authors.forename: Irwin
authors.initials: I
authors.lastname: Walot
authors.forename: Brad
authors.initials: B
authors.lastname: Spellberg
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001565:Benzoates / Q000494:pharmacology*; D001933:Brain Stem / Q000382:microbiology / Q000473:pathology; D000077336:Caspofungin; D002426:Cavernous Sinus / Q000382:microbiology / Q000473:pathology; D020314:Central Nervous System Fungal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D000077588:Deferasirox; D016883:Diabetic Ketoacidosis / Q000150:complications; D004359:Drug Therapy, Combination; D054714:Echinocandins; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D055666:Lipopeptides; D008279:Magnetic Resonance Imaging; D008297:Male; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D009668:Nose Diseases / Q000188:drug therapy* / Q000382:microbiology; D010456:Peptides, Cyclic / Q000627:therapeutic use; D016879:Salvage Therapy; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D000935:Antifungal Agents; D001565:Benzoates; D054714:Echinocandins; D007502:Iron Chelating Agents; D055666:Lipopeptides; D010456:Peptides, Cyclic; D014230:Triazoles; D000666:Amphotericin B; D000077336:Caspofungin; D000077588:Deferasirox